(Q37504669)

20 August 2017

0 references

1 reference

title

PTGS2-899G>C and prostate cancer risk: a population-based nested case-control study (ProtecT) and a systematic review with meta-analysis (English)

1 reference

20 August 2017

1 reference

1 reference

S M Collin

4

0 references

David E. Neal

7

object named as

D E Neal

1 reference

20 August 2017

A Murad

1

1 reference

20 August 2017

S J Lewis

2

1 reference

20 August 2017

G Davey Smith

3

1 reference

20 August 2017

L Chen

5

1 reference

20 August 2017

F C Hamdy

6

1 reference

20 August 2017

J Donovan

8

1 reference

20 August 2017

R M Martin

9

1 reference

20 August 2017

language of work or name

1 reference

2 June 2009

1 reference

Prostate Cancer and Prostatic Diseases

20 August 2017

1 reference

20 August 2017

12

1 reference

20 August 2017

3

1 reference

20 August 2017

296-300

1 reference

https://scigraph.springernature.com/pub.10.1038/pcan.2009.18

20 August 2017

0 references

cites work

Prostate Testing for Cancer and Treatment (ProtecT) feasibility study

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.18

Survival from prostate cancer in England and Wales up to 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.18

Global cancer statistics, 2002

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.18

A systematic review and meta-analysis of familial prostate cancer risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.18

Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.18

Inflammation in prostate carcinogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.18

Cyclooxygenase-2 and prostate carcinogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.18

Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.18

Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.18

Expression of cyclooxygenase-2 in prostate carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.18

Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.18

COX-2 gene promoter haplotypes and prostate cancer risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.18

Hypoxia induces cyclooxygenase-2 via the NF-kappaB p65 transcription factor in human vascular endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.18

Upregulation of cyclooxygenase-2 is accompanied by increased expression of nuclear factor-kappa B and I kappa B kinase-alpha in human colorectal cancer epithelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.18

Activation of both nuclear factor of activated T cells and inhibitor of nuclear factor-kappa B kinase beta-subunit-/nuclear factor-kappa B is critical for cyclooxygenase-2 induction by benzo[a]pyrene in human bronchial epithelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.18

Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.18

Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G -> C COX-2 polymorphism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.18

PTGS2 (COX-2) -765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.18

Decision-Making about PSA Testing and Prostate Biopsies: A Qualitative Study Embedded in a Primary Care Randomised Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.18

Height and prostate cancer risk: a large nested case-control study (ProtecT) and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.18

Risk factors for prostate cancer incidence and progression in the health professionals follow-up study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.18

COX2 genetic variation, NSAIDs, and advanced prostate cancer risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.18

CASP8 D302H and meningioma risk: An analysis of five case-control series

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2009.18

31 March 2020

Identifiers

DOI

10.1038/PCAN.2009.18

1 reference

Dimensions Publication ID

20 August 2017

0 references

1 reference